3 ms·
Yep. A lot of quant strategies actually exclude biotech altogether. Simply too volatile. Even with relatively conservative portfolio concentration limits you ca
by hendzen 8y ago
Yep. A lot of quant strategies actually exclude biotech altogether. Simply too volatile. Even with relatively conservative portfolio concentration limits you can still lose millions on a bio name dropping 50% due to a rumor of a failed clinical trial.